IDEXX Laboratories, Inc. (IDXX) Q3 2026 earnings results
IDEXX Laboratories, Inc. (IDXX) reported Q3 2026 results on Nov 2, 2026, 6:30:38 AM ET: GAAP EPS $4.01 vs. $3.71 expected (beat by 8.1%); revenue $1.21B. Outlook: Full year 2026 revenue guidance is $4,741 million - $4,767 million and EPS guidance is $14.96 - $15.16.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $4.01 | $3.71 | Beat by 8.1% |
| Revenue | $1.21B | — | — |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 2, 2026, 6:30:38 AM ET. Nexqual published them 49 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 9.9% from $1.11B; GAAP diluted EPS was $4.01 vs. $3.40 (+17.9%).
Stock reaction
The results came out before the market opened. IDXX closed at $671.64 on November 2, 2026, up 21.8% from its $551.21 close on October 30, 2026 before the results. Latest: $672.04 (close, November 3, 2026), +21.9% since the pre-release close.
Questions and answers
Did IDEXX Laboratories, Inc. beat earnings expectations?
Yes. IDEXX Laboratories, Inc. reported GAAP EPS of $4.01 against an average analyst estimate of $3.71 (beat by 8.1%).
What were IDEXX Laboratories, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of $4.01 and revenue of $1.21B. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 9.9% from $1.11B; GAAP diluted EPS was $4.01 vs. $3.40 (+17.9%).
When did IDEXX Laboratories, Inc. report Q3 2026 earnings?
Nov 2, 2026, 6:30:38 AM ET, in an SEC 8-K filing (Item 2.02).
How did IDXX stock react to the earnings?
The results came out before the market opened. IDXX closed at $671.64 on November 2, 2026, up 21.8% from its $551.21 close on October 30, 2026 before the results. Latest: $672.04 (close, November 3, 2026), +21.9% since the pre-release close.
What did IDEXX Laboratories, Inc. say about its outlook?
Full year 2026 revenue guidance is $4,741 million - $4,767 million and EPS guidance is $14.96 - $15.16.
More on IDXX
IDXX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 2, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 4, 2026 at 11:39 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 4, 2026 at 11:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt